Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.08 AUD | -2.44% | -3.61% | -1.23% |
03-20 | Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return | MT |
02-16 | Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses | MT |
Sales 2022 | 182K 119K 163K | Sales 2023 | 459K 300K 410K | Capitalization | 15.03M 9.82M 13.41M |
---|---|---|---|---|---|
Net income 2022 | -3M -1.96M -2.68M | Net income 2023 | -7M -4.57M -6.24M | EV / Sales 2022 | 43.1 x |
Net cash position 2022 | 29.34M 19.16M 26.17M | Net cash position 2023 | 22.47M 14.68M 20.05M | EV / Sales 2023 | -16.2 x |
P/E ratio 2022 |
-9.41
x | P/E ratio 2023 |
-1.94
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.21% |
1 day | -2.44% | ||
1 week | -3.61% | ||
Current month | -5.88% | ||
1 month | -8.05% | ||
3 months | -1.23% | ||
6 months | -60.00% | ||
Current year | -1.23% |
Managers | Title | Age | Since |
---|---|---|---|
Narelle Warren
DFI | Director of Finance/CFO | - | 19-02-28 |
Carol Parish
COO | Chief Operating Officer | - | - |
Thomas Duthy
BRD | Director/Board Member | - | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David McAuliffe
CHM | Chairman | 58 | 19-03-07 |
Narelle Warren
DFI | Director of Finance/CFO | - | 19-02-28 |
Thomas Duthy
BRD | Director/Board Member | - | 20-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.08 | -2.44% | 147,798 |
24-04-24 | 0.082 | -1.20% | 109,600 |
24-04-22 | 0.083 | 0.00% | 11,623 |
Delayed Quote Australian S.E., April 25, 2024 at 09:22 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-1.23% | 3.92M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IXC Stock